Q-Line Biotech Limited has officially announced the launch of its much-awaited SME Initial Public Offering (IPO), which will open for public subscription on May 21, 2026, and close on May 25, 2026. The company plans to raise approximately ₹214.48 crore through a completely fresh issue of equity shares, making it one of the largest SME IPOs launched in India this year. The shares are proposed to be listed on the NSE SME platform, with a tentative listing date of May 29, 2026.
The IPO price band has been fixed at ₹326 to ₹343 per equity share. According to market data, retail investors are required to apply for a minimum lot size of 400 shares, translating into an investment of around ₹1.37 lakh at the upper price band. However, some market platforms have indicated that practical retail participation may require multiple lots depending on exchange norms and application structure.
Q-Line Biotech operates in the healthcare diagnostics and In-Vitro Diagnostics (IVD) segment and is engaged in manufacturing, importing, distributing, and supplying diagnostic reagents, rapid test kits, molecular diagnostic products, pathology instruments, and healthcare consumables. The company caters to hospitals, laboratories, diagnostic centers, and healthcare institutions across India. Industry analysts believe the company is positioned to benefit from growing healthcare infrastructure investments and rising diagnostic testing demand in the country.
Founded originally as POCT Services Private Limited in 2011, the company later rebranded as Q-Line Biotech and expanded its operations aggressively across India. The company has strengthened its presence in pathology and medical diagnostic equipment markets over the last few years and reportedly serves more than 150 domestic and international clients.
Financially, Q-Line Biotech has reported strong revenue growth in FY2025. According to the latest available data, the company posted revenue of approximately ₹322.58 crore in FY2025 compared to ₹206.45 crore in FY2024, reflecting significant business expansion. However, profit after tax declined to around ₹28.13 crore from ₹34.44 crore in the previous year, mainly due to exceptional losses and rising operational expenses.
The company has also disclosed key financial performance indicators ahead of the IPO. As per FY2025 data, Q-Line Biotech reported a Return on Equity (ROE) of 17.66%, Return on Capital Employed (ROCE) of 23.74%, EBITDA margin of 22.73%, and PAT margin of 8.97%. Analysts stated that the company’s profitability ratios remain relatively healthy for an SME healthcare business despite recent earnings pressure.
According to the company’s offer documents, the IPO proceeds will mainly be utilized for working capital requirements and repayment of borrowings. Nearly ₹110 crore has been allocated toward working capital needs, while around ₹90 crore is expected to be used for repayment or prepayment of certain outstanding loans. Market experts believe debt reduction could help improve the company’s balance sheet and future financial flexibility.
The IPO has also gained market attention because prominent investor Vikas Khemani reportedly participated in a recent pre-IPO placement round. Reports suggest that the company raised nearly ₹15 crore from strategic investors ahead of the public issue, boosting visibility around the IPO in the SME market.
At the same time, market observers have highlighted several concerns linked to the company. A recent CRISIL rating downgrade reportedly cited lack of adequate information and management cooperation, raising questions around corporate governance and transparency practices. Analysts stated that investors may closely monitor these governance-related developments while evaluating the IPO.
The company also carries relatively high borrowings, with outstanding debt reportedly exceeding ₹240 crore as of December 2025. In addition, the business has high working capital requirements and significant customer concentration risk, as a large portion of revenue comes from a limited number of major clients. Industry experts believe these factors could remain important risk areas after listing.
Despite these concerns, investor sentiment around healthcare and diagnostics businesses remains positive because of India’s rapidly growing healthcare market. The Indian IVD market is expected to witness steady long-term growth due to rising healthcare awareness, increasing chronic disease diagnosis, and expansion of diagnostic infrastructure in smaller cities. Analysts believe companies operating in affordable diagnostic solutions and pathology equipment may continue to attract investor attention in the SME segment.